Learn more about the COMMANDS Trial, a phase 3 clinical research study for people with myelodysplastic syndromes (MDS) with anemia

Am I Eligible?

If you are interested in taking part in this study, begin typing your location below and then select from the dropdown list. The map will update with sites within the distance you select with a list of locations below.

Please note the map below only lists study sites that are accepting online referrals. If you cannot find a site in your area please check back again as study sites can be added to the study on an ongoing basis.

Alternatively, if you wish to see the full listing of all study sites visit clinicaltrials.gov.

Find a site near you

For more information, please watch the video.

Participation in the study lasts approximately six years (and may be shorter or longer for certain patients). This includes:
  • a screening period of approximately 35 days,
  • an initial 24-week treatment period (which may be extended if certain criteria are met and if you continue to benefit from the treatment), and
  • a follow-up period where you will be contacted approximately every 12 weeks to ask how you are doing. 

The study drug being used in the COMMANDS Trial is called luspatercept, which is a protein that aims to help increase the production of red blood cells in bone marrow. Luspatercept will be administered as an injection every three weeks during the treatment period.

The COMMANDS Trial is sponsored by Celgene, a biotechnology company committed to improving the lives of patients worldwide.

At Celgene, we recognize the importance of, and are fully committed to protecting the privacy of information related to all individuals with whom we interact. Click privacy policy to learn more.

© 2019 Celgene Corporation. All Rights Reserved